OSE Immunotherapeutics Receives €8.4 M in Public Funding for Registrational Ph 3 Trial of Cancer Vaccine Tedopi® in Lung Cancer April 16, 2024
Ph 3 Trial of MK-1084 + KEYTRUDA for 1L Treatment of Certain Patients With Metastatic NSCLC initiated April 9, 2024
Imfinzi significantly improved OS and PFS for patients with limited-stage SCLC in ADRIATIC Ph 3 trial April 8, 2024
FAILED TRIAL: Topline Results of Ph 2 KICKSTART Trial of Tomivosertib + Pembrolizumab in NSCLC announced April 8, 2024
Supplemental NDA for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients approved April 8, 2024
METIS Ph 3 Trial Met Primary Endpoint of Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Mets from NSCLC April 2, 2024
KRYSTAL-12 Trial of KRAZATI (adagrasib) Meets Primary Endpoint of PFS for Patients with Pretreated KRAS G12C-Mutated NSCLC April 2, 2024
Savolitinib Supplemental NDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC April 2, 2024
European Commission Approves KEYTRUDA + Chemo as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable NSCLC at High Risk of Recurrence in Adults April 2, 2024
Tagrisso + chemo showed favourable trend in OS in EGFR-mutated advanced lung cancer with further follow-up in FLAURA2 Ph 3 trial March 26, 2024
FAILED TRIAL: Ph 3 KEYLYNK-006 trial of KEYTRUDA + maintenance LYNPARZA did not meet dual primary endpoints of OS and PFS in 1L EGFR/ALK/ROS1 WT patients with metastatic nonsquamous NSCLC March 26, 2024
FDA accepts the NDA for ensartinib for the treatment of adult patients with metastatic ALK-positive NSCLC March 19, 2024
Biotheus Expanded Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific ADCs March 18, 2024
Taiho Pharma Enters Exclusive License Agreement with Haihe Biopharma for Gumarontinib (SCC244), an Agent for NSCLC March 12, 2024
China’s NMPA Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer March 12, 2024
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous NSCLC or HR+, HER2 Negative Breast Cancer March 12, 2024
RYBREVANT® (amivantamab-vmjw) + Chemo gets FDA approval for First-line Treatment of Patients With NSCLC with EGFR Exon 20 Insertion Mutations March 12, 2024
Vudalimab monotherapy generally well tolerated with encouraging clinical benefit for heavily-pretreated patients with high-risk metastatic CRPC March 5, 2024
